Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  GROWTH FACTORS ( BLOOD AND TISSUE )
A Global Strategic Business Report

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in Millions of US$. The major product segments analyzed are Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 90 companies including many key and niche players worldwide such as Amgen, Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Alseres Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc., GeneMedix PLC, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1217  PAGES:    576
PRICE:    $3950  DATE:       October 2008
COMPANIES:  90  MARKET DATA TABLES:   239
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  GROWTH FACTORS ( BLOOD AND TISSUE ) (Complete Report) Pages : 576   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability And Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions And Scope Of Study.....I-3
Blood Growth Factors.....I-3
  
   Erythropoietins.....I-4
Colony Stimulating Factors.....I-4
Interferons.....I-4
Interleukins.....I-4
Tissue Growth Factors.....I-4
  
II. EXECUTIVE SUMMARY84$2250
  1. Introduction.....II-12 $200  
   Growth Factors: A Preface.....II-1
Growth Factors: Their Role and Related Applications.....II-1
Growth Factors: Adding a New Dimension.....II-1
Growth Factors: Classification Based on Activity.....II-1
1$100
   Recent Trends & Developments.....II-2
Recombinant Human Erythropoietin: Gradually Gaining Dominance.....II-2
1$100
  2. Market Overview.....II-33 $400  
   Analysis by Region.....II-3
US: The Single Largest Market.....II-3
Growth Factors Market in Europe.....II-3
Market for Growth Factors in Rest of World.....II-3
Table 1: World Market for Growth Factors (2000-2010): Geographic Regions Ranked by CAGR –US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart).....II-3
1$350
   Analysis by Growth Factor Type.....II-4
EPO – The Lead ‘Factor’.....II-4
Leading EPO Drugs Worldwide.....II-4
1$100
   Market Comparison of Erythropoietin-Based Drugs in America and European Union:
  Classification Based on Key Parameters.....II-5
Patent Expiries of Major Biopharmaceutical Drugs.....II-5
1$100
  3. Market Dynamics.....II-62 $200  
   Dethroning the Leaders.....II-6
Expiration of Patents Fuels Competition and Sales.....II-6
India – At the Center Stage .....II-6
Side Effects – Still a Concern .....II-6
1$100
   CDER- A Regulatory Review Authority for Growth Factors.....II-7
1$100
  4. Outlook.....II-82 $200  
   Innovative Delivery System Shows Potential for Accelerating Use of Growth
  Factors.....II-8
Cytokines- Vital Growth Propellers for the Future of New Drugs.....II-8
Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application.....II-8
Age-Related Diseases – Their Influence on Effective Therapies.....II-8
1$100
   Copaxone Finds Novel Applications.....II-9
Mimetic Growth Factors – Exhibiting Promising Potential.....II-9
1$100
  5. Industry Issues.....II-101 $100  
   Development of Cost Effective Methods – Need of the Hour.....II-10
Influence of Neurotrophic Factors on Brain Cell Development.....II-10
Combination of Interferons and Ribavirin Develops More Anemia Cases.....II-10
1$100
  6. Competitive Trends.....II-111 $100  
   RegeneRx Focuses on Wound Healing Market.....II-11
DRL Introduces a Program to Propel its Biogenerics Business.....II-11
1$100
  7. Growth Factors – An Overview.....II-1212 $1200  
   Blood Growth Factors.....II-12
Erythropoietins.....II-12
Types of Erythropoietins.....II-12
Epoetin.....II-12
1$100
   Darbepoetin.....II-13
Aranesp®.....II-13
Aranesp Vs Other EPOs.....II-13
Recombinant Human EPO (rHuEPO).....II-13
1$100
   Table 2: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked by CAGR – Europe, US, Japan and Rest of World (includes corresponding Graph/Chart).....II-14
Colony Stimulating Factors.....II-14
Granulocyte-Colony Stimulating Factor.....II-14
Granulocyte Macrophage-Colony Stimulating Factor.....II-14
Other Colony Stimulating Factors.....II-14
1$350
   Macrophage Colony Stimulating Factor (M-CSF).....II-15
Key Functions of M-CSF.....II-15
Side-Effects of Colony-Stimulating Factors.....II-15
Table 3: World Market for Colony Stimulating Factors (2000-2010): Geographic Regions Ranked by CAGR - Japan, Europe, US, and Rest of World (includes corresponding Graph/Chart).....II-15
Interferons.....II-15
1$350
   Types of Interferons.....II-16
Interferon-gamma.....II-16
1a and 1b: Two Key Biochemical Forms of Interferon-ß.....II-16
PEG-Intron.....II-16
1$100
   Types of Interferons.....II-17
Table 4: World Market for Interferons as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart).....II-17
Interleukins.....II-17
1$350
   Types of Interleukins.....II-18 1$100
   Table 5: World Market for Interleukins as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - Europe, Japan, US, and Rest of World (includes corresponding Graph/Chart).....II-19
Tissue Growth Factors.....II-19
Wound Healing Growth Factors.....II-19
Neurotrophic Growth Factors.....II-19
Nerve Growth Factor.....II-19
1$350
   Vascular Endothelial Growth Factor (VEGF).....II-20
Fibroblast Growth Factor (FGF).....II-20
Insulin-Like Growth Factor-I (IGF-I).....II-20
Insulin-Like Growth Factor-II (IGF-II).....II-20
Tissue Growth Factors: Classification Based on Key Source and Principal
  Activity.....II-20
1$100
   Platelet – Derived Growth Factors in Wound Healing.....II-21
Thrombopoietin (TPO).....II-21
Table 6: World Market for Tissue Growth Factors (2000-2010): Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart).....II-21
Growth Factors: Their Mode of Action in Tissue Repair.....II-21
1$350
   Angiogenesis: Their Role in Wound Healing.....II-22
Angiogenesis As an Alternative for Cardiac Stents.....II-22
Applications of Growth Factors.....II-22
1$100
   Growth Factors: Application by Compound and Supplier.....II-23
Growth Factors: Indicated Applications by Site/Course of Action.....II-23
1$100
  8. Research and Development Highlights.....II-247 $500  
   Maxygen Updates on Factor VII Program .....II-24
Evaluation of Extended Dosing Schedule of PROCRIT®.....II-24
PROCRIT® - A Better Option.....II-24
Nerve Growth Factor Shows Promising Potential Against Diabetes.....II-24
1$100
   Cytokines and GM-CSF Found to be Closely Interlinked.....II-25
GM-CSF Enhances Rate of Survival in Neonates.....II-25
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients.....II-25
1$100
   rG-CSF- Their Influence on Preterm Infants with Sepsis.....II-26
Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and
  Monocyte.....II-26
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation.....II-26
1$100
   Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood
  Vessels.....II-27
Effect of Brain Derived Neurotrophic Factor on Retinal Cells.....II-27
1$100
   Orcel™ Exhibits High Growth Factor for Wound Healing and Cardiovascular
  Applications.....II-28
Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance
  Levels.....II-28
Neotrofin ™ Triggers Neurotrophic Factors.....II-28
G-CSF Shows Capability for Promoting Neutrophil Production.....II-28
1$100
   Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing
  Process.....II-29
Hepatocyte Growth Factors – Exhibiting Dual Role.....II-29
Cortex Pharmaceuticals Ampakines® Promotes Expression of Neurotrophin.....II-29
1$100
   Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates.....II-30
Cerebrolysin Promotes Cognition.....II-30
1$100
  9. Breakthroughs – A Review.....II-315 $500  
   Novel Set of Human Cytokines Unveiled.....II-31
IGFBP-3 and its Potential to Ward Off Gastric Cancer.....II-31
Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration.....II-31
Growth Factors – Their Role in Preventing Heart Stroke.....II-31
Growth Factor Proteins Shows Promising Results for Treating Cancer.....II-31
1$100
   Neurotrophic Growth Factor Primarily Responsible for Loss of Vision.....II-32
Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound
  Healing.....II-32
Role of Brain-Derived Neurotrophic Factor on Memory.....II-32
Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion.....II-32
Lipid Peroxidation May be Associated with Wound Healing.....II-32
1$100
   Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels.....II-33
Connective Tissue Growth Factor Found to Promote Lung Fibroblast.....II-33
Influence of Insulin-Like Growth Factor on Growth.....II-33
1$100
   Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair.....II-34
Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer.....II-34
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves.....II-34
Growth Factors Administration to Stimulate Tissue Repair.....II-34
Cytokine – Their Role in Combating Hepatitis C Virus.....II-34
1$100
   Axokine® Yields Favorable Results Against Obesity.....II-35
Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson’s Disease.....II-35
1$100
  10. Recent Industry Activity.....II-3612 $800  
   Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology.....II-36
ZGEN Initiates Ph II Trial of Interleukin 21.....II-36
FzioMed Bags Health Canada Approval on Oxiplex®.....II-36
NsGene A/S Implants Encapsulated Cell in Patients.....II-36
Reliance Life Sciences Takes Over Genemedix .....II-36
1$100
   Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple Sclerosis
  .....II-37
Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon.....II-37
Hemispherx Enters into Distribution Agreement with Armada.....II-37
1$100
   Bayer Launches US Pharmaceuticals Subsidiary.....II-38
Merck Inks Agreement with Bristol-Myers Squibb and ImClone .....II-38
CoGenesys Signs Global Licensing Agreement with Vegenics.....II-38
InterMune Inks New Supply Deal with Boehringer Ingelheim.....II-38
1$100
   Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals.....II-39
Cambrex Divests Bioproducts and Biopharma Subsidiaries.....II-39
Dragon Divests EPO Business.....II-39
Caregene and Genzyme Forms Partnership to Develop Cere-120.....II-39
1$100
   Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients.....II-40
NsGene to Undertake Phase Ib Clinical Trial of NsG0202.....II-40
Roche Receives European approval for NeoRecormon.....II-40
Bolder Receives Two U.S. Patents for Hematopoietic Factors.....II-40
1$100
   Hospira Receives EC Approval on Retacrit.....II-41
RLS to Initiate Clinical Trials of Erythropoietin.....II-41
InterMune Drops Phase III trial of Interferon.....II-41
Chugai to Conduct Additional Trial on Epogin®.....II-41
Merck KGaA Acquires Serono Labs.....II-41
1$100
   CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences.....II-42
Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin.....II-42
Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating
  Factor.....II-42
SII to Conduct Clinical Trials of Rdna Products.....II-42
Claris to Construct Production Facility for EOP.....II-42
1$100
   Mayne and Pliva to End Collaboration on Erythropoietin Development.....II-43
GeneMedix Collaborates with CJ Corp......II-43
FzioMed and USC Enter into Licensing Agreement for Oligopeptides.....II-43
Tercica Receives FDA Approval For Increlex.....II-43
1$100
   AnGes MG Enters Into An Agreement with Vical.....II-44
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA.....II-44
Dragon Pharmaceuticals Acquires Oriental Wave.....II-44
Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series.....II-44
Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B.....II-44
1$100
   GeneMedix Restructures Business.....II-45
pSivida Limited Collaborates with Ian Wark Research Institute.....II-45
Amgen Acquires Tularik.....II-45
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™.....II-45
1$100
   DPI Receives Approvals for Erythropoietin in Three New Markets.....II-46
Chugai and Roche Expand Drug Research Synergies.....II-46
Dragon Pharmaceuticals to Construct New Production Facility.....II-46
FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule.....II-46
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine.....II-46
Maxygen and Rentschler Enter into a Contract for G-CSF.....II-46
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon.....II-46
1$100
   Dragon Pharmaceuticals Signs Agreement with Zhongkai.....II-47
Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave.....II-47
Zymogenetics Bags US FDA Clearance.....II-47
Ceregene Bags Patent.....II-47
1$100
  11. Strategic Corporate Developments in Recent Past.....II-485 $500  
   AME Enters into Third Collaboration with Eli Lilly and Company.....II-48
ViaCell Enters into Licensing Agreement and Collaboration with Amgen.....II-48
Ceregene Enters into Licensing Agreement with Genentech.....II-48
BIOPHARM GmbH Enters into Licensing Contract with DePuy.....II-48
Maxygen Enters into a Deal with Roche Holding.....II-48
1$100
   Dragon Pharmaceuticals Bags Market Approval from Chinese SDA.....II-49
GeneMedix Signs Agreement with SkyePharma.....II-49
Neurotech Enters into Licensing Agreement with Amgen.....II-49
Ceregene Enters into a Licensing Agreement with Washington University.....II-49
NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis.....II-49
BioSET Bags Global Exclusive License for Novel Growth Factor Technology.....II-49
1$100
   ViaCell Acquires Cerebrotec.....II-50
Fibrogen Collaborates with Sankyo.....II-50
Prescient NeuroPharma Collaborates with SRIB.....II-50
Dragon Pharmaceuticals Signs Agreement with Renapharm AB and Transworld.....II-50
Baxter Bags Exclusive Worldwide Rights for Epoetin Omega.....II-50
Ortec International Bags FDA PMA for OrCel.....II-50
1$100
   GeneMedix Bags Chinese SDA Approval.....II-51
NsGene Collaborates with ARIAD Pharmaceuticals.....II-51
Regeneron Enters into Agreement with Emisphere Technologies.....II-51
NsGene A/S Signs Agreement with Biogen Inc.....II-51
1$100
   NTB Enters into BioInformatics Outsourcing Agreement with HSC.....II-52
1$100
  12. Product Launches in Recent Past.....II-531 $100  
   Wockhardt Introduces Wepox Recombinant Erythropoietin Drug.....II-53
Shanta Biotechnics Unveils Shanferon.....II-53
SkinMedica Unveils TNS Recovery Complex™ Gel.....II-53
CellGenix Unveils Cytokines for Cell Applications.....II-53
Cel-Sci Corporation Develops Multikine.....II-53
Wockhardt Limited Unveils EPOX™.....II-53
1$100
  13. Focus on Select Global Players.....II-547 $500  
   Amgen, Inc. (USA).....II-54
BioMimetic Therapeutics, Inc. (USA).....II-54
Biopharm GmbH (Germany).....II-54
Bolder Biotechnology, Inc. (USA).....II-54
1$100
   Alseres Pharmaceuticals, Inc. (USA).....II-55
Ceregene Inc. (USA).....II-55
FibroGen Inc. (USA).....II-55
FzioMed Inc. (USA).....II-55
1$100
   GeneMedix Plc. (UK).....II-56
Insmed Inc. (USA).....II-56
Johnson & Johnson (USA).....II-56
1$100
   Janssen-Ortho Inc. (Canada).....II-57
Lonza Group (Switzerland).....II-57
Maxygen, Inc. (USA).....II-57
Merck Serono International S.A. (Switzerland) .....II-57
1$100
   NsGene A/S (Denmark).....II-58
PeproTech Inc. (USA).....II-58
Rentschler Biotechnologie GmbH (Germany).....II-58
F. Hoffmann-La Roche Ltd (Switzerland).....II-58
1$100
   Chugai Pharmaceutical Co. Ltd. (Japan).....II-59
Genentech Inc. (USA).....II-59
Shantha Biotechnics (India) .....II-59
1$100
   Scil Proteins GmbH (Germany).....II-60
Wockhardt Ltd. (India).....II-60
1$100
  14. Global Market Perspective.....II-61   
   Table 7: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-611$350
   Table 8: World Long-term Projections for Growth Factors (Blood and Tissue) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-621$350
   Table 9: World 10-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-631$350
   Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-641$350
   Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type – Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-651$350
   Table 12: World Long-term Projections for Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-661$350
   Table 13: World Long-term Projections for Blood Growth Factors by Type – Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 14: World 10-Year Perspective for Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-681$350
   Table 15: World 10-Year Perspective for Blood Growth Factors by Type – Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-691$350
   Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-701$350
   Table 17: World Long-term Projections for Erythropoietins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-711$350
   Table 18: World 10-Year Perspective for Erythropoietins by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-721$350
   Table 19: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-731$350
   Table 20: World Long-term Projections for Colony Stimulating Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-741$350
   Table 21: World 10-Year Perspective for Colony Stimulating Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-751$350
   Table 22: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-761$350
   Table 23: World Long-term Projections for Interferons as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-771$350
   Table 24: World 10-Year Perspective for Interferons as Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-781$350
   Table 25: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-791$350
   Table 26: World Long-term Projections for Interleukins as Blood Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-801$350
   Table 27: World 10-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-811$350
   Table 28: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-821$350
   Table 29: World Long-term Projections for Tissue Growth Factors by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-831$350
   Table 30: World 10-Year Perspective for Tissue Growth Factors by Geographic Region – Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-841$350
III. MARKET38$1950
  1. The United States.....III-114 $950  
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
EPO Market Scenario.....III-1
Key Market Driver for EPO.....III-1
Leading EPO Drugs in the US.....III-1
1$75
   Recent Industry Activity.....III-24$300
   Strategic Corporate Developments in Recent Past.....III-62$150
   Product Launches in Recent Past.....III-81$75
   Key Players.....III-93$225
   B. Market Analytics.....III-12
Table 31: US Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-12
1$200
   Table 32: US Long-term Projections for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-131$200
   Table 33: US 10-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-14
1$200
  2. Japan.....III-155 $575  
   A. Market Analysis.....III-15
Current and Future Analysis.....III-15
Erythropoietin Market: Competitive Scenario.....III-15
Leading EPO Drugs in Japan.....III-15
Market Scenario for Biotech Products.....III-15
Biotech Market Backed by Public Assistance.....III-15
1$75
   Recent Industry Activity.....III-16
Chugai Pharmaceutical Co. Ltd. – A Key Player.....III-16
1$75
   B. Market Analytics.....III-17
Table 34: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-17
1$200
   Table 35: Japanese Long-term Projections for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-181$200
   Table 36: Japanese 10-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-19
1$200
  3. Europe.....III-2010 $775  
   A. Market Analysis.....III-20
Current and Future Analysis.....III-20
Erythropoietin Market Scenario in the Recent Past.....III-20
Leading EPO Drugs in Europe.....III-20
Recent Industry Activity.....III-20
2$150
   Strategic Developments in Recent Past.....III-222$150
   Product Launch in Recent Past.....III-24
Key Players.....III-24
3$225
   B. Market Analytics.....III-27
Table 37: European Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-27
1$200
   Table 38: European Long-term Projections for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-281$200
   Table 39: European 10-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-29
1$200
  4. Rest of World.....III-309 $750  
   A. Market Analysis.....III-30
Current and Future Analysis.....III-30
An Overview of Indian Market.....III-30
Erythropoiet III-30 G-CSF .....III-30
1$75
   Interferon.....III-31
Recent Industry Activity.....III-31
2$150
   Strategic Developments in Recent Past.....III-331$75
   Product Launches in Recent Past.....III-341$75
   Key Players.....III-351$75
   B. Market Analytics.....III-36
Table 40: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-36
1$200
   Table 41: Rest of World Long-term Projections for Growth Factors by Type – Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-371$200
   Table 42: Rest of World 10-Year Perspective for Growth Factors by Type – Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-381$200
IV. COMPETITIVE LANDSCAPE 435$995
  
Total Companies Profiled: 90 (including Divisions/Subsidiaries - 101)

Region/Country                 Players


The United States                 55
Canada                             3
Japan                              5
Europe                            24
     Germany                      11
     The United Kingdom            2
     Rest of Europe               11
Asia-Pacific (Excluding Japan)    14
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.